Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydronidone PK in Renal Insufficiency
NCT07262333Phase 1Recruiting
- Sponsor
- Gyre Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hydronidone in Liver Fibrosis (LF) (4 arms), sponsored by Gyre Pharmaceuticals. Primary endpoints: Area Under the Curve from Zero to Infinity at 48 hours, Free plasma concentration of hydronidone at 48 hours and 9 more. Started Dec 2025; status: recruiting.
02
Drugs
hydronidone
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT07262333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07262333.